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Kynurenic acid (KYNA) is one of many kynurenine intermediate products in the tryptophan 
metabolism pathway and has been shown to have neuro-activity.  Previous work revealed that 
prolonged infusion of a high dose of KYNA could effectively reduce the myelin content in 
the rat spinal cord.  We hypothesize that prolonged subdural infusion of kynurenic acid 
(KYNA) induces myelin loss in the optic nerves of chickens. 
Seven day old gallus gallus domesticus chickens were randomly selected for infusion 
of 50 mM KYNA or phosphate buffered saline (PBS).  KYNA or PBS were loaded into an 
osmotic pump that was attached to a catheter.  The catheter was inserted into the optic nerve 
and the pump was implanted under the skin in upper back region of the bird.  A third group of 
birds received no treatment.  Electron micrographs were collected and the percent of 
myelinated axons, g-ratios, the number of astrocytes, and the axon diameters were calculated 
by sampling from 4 quadrants of optic nerve sections.  Enzyme-linked immunosorbent assays 
(ELISA) were performed on serum from the three groups in order to determine differences in 
the level of myelin proteins myelin basic protein (MBP) and proteolipid protein (PLP).  
Semi-quantitative analysis of western blots was performed for myelin proteins: MBP, PLP, 
and myelin associated glycoprotein (MAG) in addition to glial fibrillary acidic protein 
(GFAP).  A 2x3 mixed model analysis of variance (ANOVA) was used to determine 
differences between the three treatment groups and eyes.  Count data were analyzed using 
two one-way Kruskal-Wallis ANOVAs. 
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Electron microscopy revealed that KYNA-infused nerves exhibited widespread loss 
of myelin sheaths and astrogliosis without inflammatory infiltration of the nerve.  G-ratios 
for KYNA-infused chicks were greater than those for negative control birds (0.86 ± 0.04 for 
KYNA vs 0.78 ± 0.02 for NC; p = 0.0029) but were not significantly greater than compared 
to PBS-infused chicks (0.83 ± 0.06; p = 0.2605).  ELISAs revealed no differences in the 
concentration of serum MBP or PLP across the three treatment groups indicating a non-
destructive effect on myelin in the nerve (p = 0.8330 and p = 0.8759, respectively).  Lastly, 
western blots revealed a qualitative reduction in the level of MBP and PLP, and GFAP in 
KYNA-infused birds compared to PBS-infused or negative control birds. 
Subdural infusion of 50 mM KYNA for 7 days induces myelin loss without 
inflammatory infiltration in the chicken optic nerve.  KYNA may be useful for illuminating 
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I: LITERATURE REVIEW 
1.1 The nervous system 
The functional unit of the nervous system is a cell called a neuron (Figure I-1).   A neuron 
consists of a cell body, dendrites and axon (Ramón y Cajal; Nolte, 2009) Neurons can 
communicate with each other by first sending electrical signals down the length of their axons 
(Hodgkin and Huxley, 1952; Nolte, 2009).  At the end of the axon, neurotransmitters are released 
into the synaptic space between the end of the axon and the tip of the dendrite (Hodgkin and 
Huxley, 1952; Nolte, 2009).  Neurotransmitters received at the post synaptic membrane, as a 
chemical signal, are converted back into an electrical signal which travels through the neuron 
and axon again (Hodgkin and Huxley, 1952; Nolte, 2009).  Different types of neurons can 
 
Figure I-1.  Structure of a typical neuron.  A neuron consists of the cell body, dendrites, axon 
and axon terminals.  Dendrites receive signals from other neurons.  The signal is passed down 
the cell body and axon and transmitted to other neurons through the axon terminals.  Myelin 








respond to unique modalities of stimuli and regulate different processes by sending signals to or 
from the brain (Nolte, 2009).  For example, sensory neurons can respond to light, sound, odor, 
taste, pressure and heat and send messages to the brain (Nolte, 2009).  Motor neurons transmit 
messages from the brain to control voluntary and involuntary movement (Nolte, 2009).  In 
addition to neurons, non-neuronal cells called glial cells, provide support, nutrition, maintain 
homeostasis, form myelin, and participate in signal transmission in the nervous system (Nolte, 
2009).  
The vertebrate nervous system consists of the central nervous system (CNS) and the 
peripheral nervous system (PNS).  The CNS consists of the brain and spinal cord while the PNS 
consists of the nerves and ganglia outside of the brain and spinal cord (Nolte, 2009). 
1.1.1 Development of the nervous system 
Development of the vertebrate nervous system begins during the third week of embryonic 
development (Nolte, 2009). In response to signals released from the midline mesoderm, a 
longitudinal band of ectoderm thickens, forming the neural plate (Nolte, 2009; Figure I-2A).  
The neural plate folds inward to form the neural groove, flanked by parallel neural folds (Nolte, 
2009), which approach each other in the dorsal midline as the neural groove deepens.  By the end 
of the third week, the neural folds fuse midway along the neural groove, starting the formation of 
the neural tube (Nolte, 2009).  By the end of the fourth week, additional sites of fusion appear, 
forming the entire neural tube (Nolte, 2009).  The neural tube progressively separates from the 
ectodermal surface becoming enclosed within the body (Nolte, 2009).  Cells from the crest of 
each neural fold develop into sensory neurons of the ganglia of spinal nerves, the postganglionic 
neurons of the autonomic nervous system (ANS), and the Schwann cells and satellite cells of the 
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PNS (Nolte, 2009).  The neural tube develops into the CNS and its cavity develops into the 
ventricular system of the brain (Nolte, 2009). 
During the fourth week, three bulges, referred to as the primary vesicles appear (Nolte, 
2009; Figure I-2B).  The most rostral is the prosencephalon, followed by the mesencephalon and 
finally the rhombencephalon.  These vesicles merge smoothly with the spinal portion of the 
neural tube (Nolte, 2009).  The prosencephalon develops into the cerebrum while the 
mesencephalon becomes the midbrain.  The rhombencephalon develops into the rest of the 
brainstem and the cerebellum (Nolte, 2009).    During the fifth week, the prosencephalon divides 
into the telencephalon and the diencephalon while the rhombencephalon divides into the 
metencephalon and the myelencephalon (Nolte, 2009).  The telencephalon develops into the 
cerebral hemispheres (Nolte, 2009) and the diencephalon gives rise to the thalamus, the 
 
Figure I-2. Embryonic development of the vertebrate nervous system.  A) The neural plate 
forms from the ectoderm (ECT), under which lies the notochord (N).  During neurulation, the 
midline of the plate forms the neural fold.  Fusion of the neural folds gives rise to the neural 
tube.  Neural crest cells (NC) migrate from the dorsal region of the neural tube.  B) Three 
primary vesicles develop that will give rise to the major structures of the brain.  C)  Secondary 



























hypothalamus, the retina, the optic nerve and several other structures (Nolte, 2009).  The 
metencephalon becomes the pons and the cerebellum while the myelencephalon becomes the 
medulla (Nolte, 2009). 
1.1.2 Central nervous system 
The brain and spinal cord is made of white and gray matter (Purves et al., 2001).  Gray matter 
comprises of the neurons cell bodies and dendrites while white matter comprises of the axons 
(Purves et al., 2001).  The brain integrates, processes and coordinates the information it receives 
(Purves et al., 2001).  The spinal cord acts as a relay for motor and sensory information and 
coordinates certain reflexes.  Motor information is transmitted from the brain down the spinal 
cord to the effector muscles while sensory information is relayed up the spinal cord to the brain.  
The glial cells of the CNS include astrocytes, oligodendrocytes, microglia and ependymal cells 
(Purves et al., 2001).  Astrocytes have star-like processes and are responsible for maintaining an 
appropriate chemical environment for neuronal signalling (Purves et al., 2001).  
Oligodendrocytes are responsible for wrapping multiple axons with a lipid-rich sheath called 
myelin (Purves et al., 2001).  Myelin insulates the electrical signals as they travel down the axon, 
allowing for faster transmission of the signals (Purves et al., 2001).  Microglial cells are 
phagocyte-like cells that scavenge for cellular debris from injury or normal cell turnover (Purves 
et al., 2001).  Microglial cells can proliferate from resident microglia in the brain or migrate to a 
site and infiltrate the injured area from the blood stream (Purves et al., 2001).  Lastly, ependymal 
cells are the thin epithelial lining of the ventricles of the brain and the spinal cord (Purves et al., 
2001).  These cells are responsible for the production of cerebrospinal fluid (CSF), which 
nourishes and protects the central nervous system from mechanical injury (Purves et al., 2001).   
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The CNS is also protected by membranous coverings, called the meninges, which 
stabilize the position of the CNS (Nolte, 2009).  The meninges are composed of three different 
layers.  The outermost layer is the dura, followed by the arachnoid and the pia (Nolte, 2009).  
The dura is the thickest layer and is attached to the inner surface of the skull while the arachnoid 
adheres to the inner surface of the dura and the pia is attached to the brain.  The space between 
the arachnoid and pia is filled with CSF and contains blood vessels (Nolte, 2009). 
1.1.3 Peripheral nervous system 
The PNS can be further divided into the ANS and the somatic nervous system (SNS) (Nolte, 
2009).  The ANS regulates processes in the body that are not consciously controlled, such as 
breathing and metabolic processes, while the SNS controls voluntary processes such as 
movement of the limbs (Nolte, 2009).  Glial cells of the PNS include Schwann cells and satellite 
cells (Nolte, 2009).  Unlike the oligodendrocytes, Schwann cells produce myelin around the 
axons of only a single neuron (Nolte, 2009).  Schwann cells are also involved in regeneration 
and development of the neurons (Nolte, 2009).  Satellite cells are similar to astrocytes in the 
CNS and play a role in regulating the environment in PNS ganglia (Nolte, 2009). 
1.1.4 Regeneration of the nervous system 
CNS axons do not readily regenerate after injury, whereas PNS axons do, allowing for recovery 
of function after peripheral nerve damage.  Aguayo and colleagues have demonstrated that CNS 
neurons have the capacity to regenerate within the permissive environment of the PNS 
(Richardson et al., 1980; David and Aguayo, 1981; Benfey and Aguayo, 1982).  These studies 
suggested that neurons of the CNS are not intrinsically limited in their regenerative potential.  
Rather, the CNS has an inhibitory environment limiting the regenerative potential, whereas the 
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PNS has a stimulatory environment for axon regrowth.  Indeed, growth promoting factors in the 
PNS and growth-inhibiting factors in the CNS have been implicated in axon regrowth.  The 
upregulation of these factors is a consequence of the events that occur post-injury. 
 After injury to a peripheral nerve, the distal portion of the axon undergoes Wallerian 
degeneration (Figure I-3).  This process leads to the disintegration of the axon.  Within hours 
following injury, macrophages migrate to the site of injury to remove the debris (Faroni et al., 
2015).  In the first 24 hours, Schwann cells proliferate and switch from a myelinating to 
regenerating phenotype, where upregulation of molecules to assist in the degenerative and 
regenerative processes occurs (Faroni et al., 2015).  Structural proteins, such as myelin basic 
protein and myelin associated glycoprotein are downregulated while cell adhesion molecules, 
 
Figure I-3. Regenerative process in the PNS.  Following injury and Wallerian degeneration, 
Schwann cells detach from axons and proliferate into a regenerative mode. In the regenerative 
mode, Schwann cells upregulate the expression of stimulatory factors, which creates a favorable 
environment for nerve regrowth and guidance.  Figure reprinted from Faroni et al. (2015) with 
permission from Elsevier. 
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glial fibrillary acidic protein (GFAP) and growth factors – nerve growth factor (NGF), brain-
derived growth factor (BDNF), glial-derived neurotrophic factor (GDNF), basic fibroblast 
growth factor (bFGF) and neurotrophin 3 (NT-3) are upregulated (Faroni et al., 2015).  
Following removal of the debris, Schwann cells align into tubes called column bands of Bünger, 
which enable guided axonal regeneration in permissive environments that are rich in trophic 
factors (Faroni et al., 2015). 
After injury to CNS nerves, the distal ends of the axons form retracting dystrophic 
 
Figure I-4. Injury of axons in the CNS leads to the formation of a glial scar.  MAIs and 
CSPGs create an inhibitory environment for axon regrowth.  Figure reprinted from Yiu and He 
(2006) with permission from Nature Publishing Group. 
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growth cones  (Yiu and He, 2006).  During the early phase of injury, myelin associated inhibitors 
(MAIs) from intact oligodendrocytes restrict axon regrowth (Yiu and He, 2006).  Next, 
recruitment of inflammatory cells and reactive astrocytes leads to the formation of a glial scar 
(Yiu and He, 2006; Figure I-4).  The scar formation presents a physical barrier for regrowth and 
is also associated with an increased production of chondroitin sulphate proteoglycans (CSPGs), 
which further limits regeneration (Yiu and He, 2006). 
Several of the myelin components expressed by the oligodendrocytes are MAIs.  
Mammalian CNS myelin predominantly consists of MBP and proteolipid protein (PLP) (Siegel 
et al., 1999), with MBP comprising about 30% of the myelin sheath and PLP comprising another 
40% (Siegel et al., 1999).  In contrast, the major PNS myelin protein is myelin protein zero (P0) 
and accounts for more than half of the PNS myelin protein, while MBP in the PNS accounts for 
5 to 18% of total protein (Siegel et al., 1999).  The remainder of the proteins in the CNS that 
make up the myelin sheath consists of other proteins and glycoproteins (Siegel et al., 1999), 
some of which are MAIs.  These proteins include Nogo-A, myelin-associated glycoprotein 
(MAG), myelin oligodendrocyte glycoprotein (MOG), ephrin-B3 and semaphoring 4D (Huebner 
and Strittmatter, 2009).  Nogo-A, MAG and MOG interact directly with a neuronal Nogo-66 
receptor (NgR1) which limits axon growth (Huebner and Strittmatter, 2009).  Except for MAG, 
these MAIs are not produced by Schwann cells in the PNS (Huebner and Strittmatter, 2009).  
Still, MAG in the PNS is cleared away rapidly by glial cells in the periphery, unlike in the brain 
and spinal cord (Huebner and Strittmatter, 2009).  Studies have demonstrated that removal of 
MAIs or blocking of the NgR1 receptor can promote regrowth in the CNS.  Deletion of the 
Nogo-A gene in knockout mice has led to promotion of corticospinal tract growth and 
enhancement of functional recovery (Simonen et al., 2003).  Additionally, antibodies targeted 
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against Nogo-A promote axonal growth after CNS injury (Wiessner et al., 2003).  Although 
MAG has been shown to inhibit neurite outgrowth, no enhanced corticospinal tract regeneration 
was observed in MAG knockout mice (Bartsch et al., 1995).  Consequently, MAG may have less 
of an impact in limiting axon regrowth in the CNS compared to other MAIs.  However, knockout 
of the NgR1 in mice led to differentially enhanced spinal tracts regrowth after spinal cord injury 
(Kim et al., 2004).  Moreover, regrowth of corticofugal axons was observed in these mice after a 
stroke (Li et al., 2004).  Thus, the method or location of injury in the CNS may be important 
factors for determining how MAIs will interfere with regeneration. 
 The astroglial scar, which forms as a result of reactive astrocytes, creates a physical 
barrier to regeneration and inhibits axon regrowth in the CNS (Yiu and He, 2006).  The glial 
reaction to injury results in the recruitment of microglia, oligodendrocyte precursors, meningeal 
cells and astrocytes to the lesion site (Yiu and He, 2006).  Many of the astrocytes become 
reactive, marked by an increase in GFAP, releasing CSPGs and other inhibitory extracellular 
matrix molecules (Yiu and He, 2006).  CSPGs are the main inhibitory molecule found in the glial 
scar (Huebner and Strittmatter, 2009).  They include neurocan, versican, brevican, phosphacan, 
aggrecan, and NG2 (Huebner and Strittmatter, 2009).  A specific receptor for these molecules 
have not been identified (Huebner and Strittmatter, 2009).  However, modifying the structure of 
CSPGs can promote regeneration.  Specifically, CSPGs contain core proteins with 
glycosaminoglycan side chains, which, when cleaved by the bacterial enzyme chondroitinase 
ABC, reduces their inhibitory activity (Bradbury et al., 2002). 
 Inflammation within the CNS also acts to inhibit the regenerative potential of axons.  
Microglial cells from the CNS and activated macrophages from the blood respond to trauma in 
the brain and spinal cord after injury (Fitch and Silver, 2008).  These cells release their own 
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sources of cytokines and signaling molecules, leading to the upregulation of inhibitory 
molecules.  The inflammatory response contributes to secondary damage after the primary insult 
(Fitch and Silver, 2008).  Indeed, injection of an inflammation inducing agent in an in vivo 
model leads to significant axotomy and an upregulation of reactive astrocytes (Fitch and Silver, 
2008).  In contrast, some elements of CNS inflammation have been suggested to be 
neuroprotective.  For example, macrophages can secrete growth promoting factors such as 
neurite growth factor and neurotrophin-3 (Elkabes et al., 1996).  Moreover, when zymosan is 
placed in the vitreous chamber of the eye, it can stimulate regeneration of optic nerve fibers 
(Leon et al., 2000).  Unfortunately, inflammation tends to create cavitation and scarring in the 
CNS in the absence of any primary physical injury (Fitch and Silver, 2008). It is unclear whether 
modifying immune cell activity could lead to functional regeneration within the CNS. 
1.2 The eye and optic nerve 
The vertebrate eye is an organ that allows an organism to detect light and process visual 
information.  The human eye consists of several structures to help with this function (Figure I-5).  
 
Figure I-5.  Anatomy of the human eye.  Figure reprinted from Kolb et al. (1995). with 
permission from http://webvision.med.utah.edu/. 
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A transparent layer of cells called the cornea acts to refract light entering the eye and cover the 
pupil and iris (Kolb et al., 1995).  The pupil allows light to enter the eye while the iris is a 
circular muscle that controls the size of the pupil, thus controlling the amount of light that enters 
the eye (Kolb et al., 1995).  Light is further and primarily refracted by the crystalline lens to 
produce a sharp image at the retina where the light is converted to an electrical signal by the 
neurons of the retina (Kolb et al., 1995).  This electrical signal is then sent to the brain via the 
optic nerve.  The ciliary body and zonule fibers can also change the shape of the lens through a 
process known as accommodation, to focus the light onto the retina (Kolb et al., 1995).  The 
outermost layer of the human eye (Figure I-5), the sclera, is continuous with the cornea (Kolb et 
al., 1995).  The intermediate layer consists of the choroid and the innermost layer is the retina 
(Kolb et al., 1995).  The eye also consists of three chambers of fluid that provide nutrients to the 
various components of the eye.  The anterior chamber, between the cornea and iris, and the 
poster chamber, between the iris, zonule fibers and lens is filled with aqueous humor (Kolb et al., 
1995).  The aqueous humor maintains the intraocular pressure and inflates the globe of the eye 
(Kolb et al., 1995).  The vitreous chamber, between the lens and the retina, is filled with vitreous 
humor (Kolb et al., 1995).  The vitreous humor is an immobile gel-like substance that helps to 
hold the spherical shape of the eye and keep the retina in place (Kolb et al., 1995). 
1.2.1 Development of the eye and optic nerve 
Development of the vertebrate eye begins in the primitive forebrain (Oyster, 1999).  Two small 
bumps, referred to as optic pits, appear on either side of the neural tube as the rostral end closes 
(Oyster, 1999; Figure I-6).  These pits form the beginning of the eyes and develop as a 
symmetric pair (Oyster, 1999).  The pit undergoes cell proliferation to become a spherical vesicle 
connected to the neural tube by a cylindrical optic stalk (Oyster, 1999).  Both the vesicle and 
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stalk are hollow structures consisting of a layer of epithelial cells.  These cells continue to 
expand but are limited by the surface ectoderm (Oyster, 1999).  The optic vesicle then induces 
the surface ectoderm to form a lens (Oyster, 1999).  As the lens forms, the optic cup invaginates 
more deeply to form the choroidal fissure (Oyster, 1999).  The choroidal fissure appears along 
the inferior surface of the optic cup and stalk.  With formation of the choroidal fissure, a blood 
vessel gains access into the optic stalk and extends to the rim of the cup and lens.  This vessel 
begins as the hyaloid artery to supply the developing lens and portions of it eventually become 
the central retinal artery (Oyster, 1999).  About 5-6 weeks into gestation, the choroidal fissure 
 
Figure I-6.  Development of the vertebrate eye.  A) An invagination from the diencephalon 
forms the optic vesicle. B) The optic vesicle contacts the surface ectoderm (SE) resulting in the 
formation of the future RPE, retina (NR) and optic stalk (OS) while the surface ectoderm forms 
the lens placode (LP).  C) The optic stalk and lens placode invaginates to form the optic cup and 
lens vesicle (LV).  D)  The optic cup forms a bilayered hemisphere of the RPE and retina while 
the lens develops.  E)  The lens (L) becomes solid, and the optic stalk develops into the optic 
nerve (ON).  The surface ectoderm gives rise to the corneal epithelium (C) and sclera (S).  Figure 
adapted from Adler and Canto-Soler (2007) with permission from Elsevier. 
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closes and fusion of subsequent layers results in the optic cup assuming the form of a two-
layered hemisphere (Oyster, 1999).  At this point, the cells of the posterior part of the lens vesicle 
differentiate into lens fibers.  These lens fibers will continue to develop to form the lens (Oyster, 
1999). The outer rim of the cup will contribute to the iris, ciliary body and iris muscles, while the 
surface ectoderm will develop into the future corneal epithelium (Oyster, 1999).  The mesoderm 
will eventually develop into the extraocular muscles, the orbit, and orbital vessels (Oyster, 1999).  
Meanwhile the optic cup and optic stalk represent the beginning of the retina and optic nerve, 
respectively (Oyster, 1999; Figure I-6). 
The outer layer of the cup differentiates first, eventually producing the pigment 
epithelium in a center-to-periphery gradient (Oyster, 1999).  Meanwhile, differentiation of the 
inner layer of the optic cup involves a thickening of a layer of stem cells and a migration of cells 
to eventually form the sensory retina (Oyster, 1999).  These cells have the capacity to become 
any of the mature cell types in the retinas (Oyster, 1999).  First retinal ganglion cells (RGCs), 
horizontal cells, and cones develop followed by amacrine cells, Müller cells, bipolar cells and 
rods (Oyster, 1999).  Again, these cells develop in a center-to-periphery gradient, in the same 
order (Oyster, 1999).  Synaptic connections develop a week after the first cells develop with the 
same gradient pattern (Oyster, 1999).  Most of the neural connections within the retina are 
established by 5 months of gestation (Oyster, 1999).  The synapses occur within two plexiform 
layers while the cell bodies of the retinal neurons are located in three nuclear layers (Figure I-7).  
The last structure to develop in the retina is the fovea.  At the fovea, ganglion cell nuclei migrate 
radially outwards leaving an area of almost entirely developing cone cells, providing high visual 
acuity (Oyster, 1999).  Foveal development continues until after about 4 years of birth (Oyster, 
1999).  After the initial wave of cells that develop in the central retina, vascular precursor cells 
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also appear eventually leading to the formation of blood vessels along the inner surface of the 
retina (Oyster, 1999). 
The optic stalk is a hollow cylinder of neuroepithelial cells and folds inward to become a 
double-walled tube (Oyster, 1999).  At this point, the stalk consists of three concentric parts: the 
central core and intermediate and outer sheaths of neuroepithelium (Oyster, 1999).  The 
intermediate sheath will give rise to glial cells, including astrocytes and oligodendrocytes, within 
the nerve, while the outer sheath will become the outermost glial sheath of the nerve (Oyster, 
 
Figure I-7.  3-D block of a human retina. Photoreceptor nuclei are located in the outer nuclear 
layer (ONL) and synapse onto bipolar cells and horizontal cells in the outer plexiform layer 
(OPL). The nuclei of the bipolar, horizontal and amacrine cells are located in the inner nuclear 
layer (INL).  Bipolar cells synapse with ganglion cells in the inner plexiform layer (IPL).  
However, amacrine and horizontal cells also influence the signals between the bipolar and 
ganglion cells.  The ganglion cell nuclei are located in the ganglion cell layer (GCL) and their 
axons form the nerve fiber layer (NFL).  Figure reprinted from Kolb et al. (1995) with 
permission from http://webvision.med.utah.edu/. 
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1999).  As axons from developing ganglion cells reach the nerve, the inner cells of the nerve core 
degenerate or differentiate into glial cells providing a path for the axons to the brain (Oyster, 
1999).  The optic nerve forms as the optic stalk is replaced by developing RGC axons and glial 
cells (Oyster, 1999).  The growth of the dorsal part of the neural tube tends to push the stalks 
together eventually causing them to merge before arrival of the axons from the eyes.  This fusion 
of the stalks produces the optic chiasm (Oyster, 1999).  The retinotopic distribution of axons in 
the nerve and chiasm is retained and provides directions for the ipsilateral or contralateral path 
(Oyster, 1999).  Finally, at about fetal week 15, oligodendrocytes in the nerve begin to form 
myelin sheaths around the axons in a center-to-periphery gradient reaching the lamina cribrosa 
before birth where myelination stops (Oyster, 1999).  About 90% of the tract axons will project 
to the lateral geniculate nucleus (LGN) on either side of the midbrain as part of the primary 
visual pathway (Oyster, 1999).  Meanwhile, the other 10% of the ganglion cell axons will 
terminate in other regions of the brain such as the superior colliculus, the pretectal nuclei, and 
the suprachiasmatic nucleus for other functional associations (Oyster, 1999). 
1.2.2 Diseases of the optic nerve 
The optic nerve is part of the CNS.  Consequently, like the brain and spinal cord, the optic nerve 
does not readily regenerate after injury.  Injury to the optic nerve typically results in permanent 
loss of axons and RGCs.  Consequently, loss of the RGCs results in vision loss or blindness 
depending on the severity of the damage.  The most common diseases to affect the optic nerve 
are glaucoma, inflammatory optic neuritis and ischemic optic neuropathy (Margalit and Sadda, 
2003). 
Glaucoma is a disease characterized by the progressive degeneration of RGCs, cupping 
of the optic nerve, and visual loss (review by Weinreb et al., 2014).  Glaucoma is currently the 
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leading cause of irreversible blindness worldwide, affecting more than 70 million people 
(Weinreb et al., 2014).  The biological basis of the disease remains poorly understood, and 
affected individuals could be asymptomatic until signs of damage become apparent (Weinreb et 
al., 2014).  There are several types of glaucoma, however the most common, open-angle 
glaucoma, represents more than 80% of the cases observed (Weinreb et al., 2014).  Currently, 
intraocular pressure is the most important risk factor associated with glaucoma (Weinreb et al., 
2014).  An increase in intraocular pressure, due to an imbalance of aqueous humor production 
and secretion, results in mechanical stress and strain on the structures of the back of the eye, 
namely the lamina cribrosa (Weinreb et al., 2014).  The lamina cribrosa is where the sclera 
passes through the axons of the RGCs in a mesh-like fashion.  It presents the weakest point in 
the wall of the eye.  Consequently, pressure-induced strain, compression, deformation or 
remodelling of the axons can all result in mechanical damage to the axons and disrupt axonal 
transport and ultimately result in the degeneration of RGCs via apoptosis (Weinreb et al., 2014). 
Optic neuritis is a demyelinating inflammation of the optic nerve.  There are several 
clinical classifications of optic neuritis (review by Toosy et al., 2014).  However, it is most 
commonly associated with multiple sclerosis (MS), an autoimmune disease of the CNS that 
targets myelin and results in inflammation and vision loss (Toosy et al., 2014).  The pathology 
presents itself as lesions in the optic nerve, similar to plaque formation in the brains of MS 
patients (Toosy et al., 2014).  In the early phase of the disease, inflammatory demyelination 
occurs, resulting in conduction block and visual loss (Toosy et al., 2014).  T-cell, B-cell and 
microglial activation occurs with a release of pro-inflammatory cytokines (Toosy et al., 2014).  
However, the specific mechanism and target antigens are unknown.  Several weeks following an 
acute episode, inflammation resolves and visual function and remyelination are incompletely 
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restored (Toosy et al., 2014).  Additionally, damaged axons become more vulnerable to future 
inflammatory episodes (Toosy et al., 2014). While a high dose of intravenous corticosteroids 
could speed the recovery of visual function, it does not have an effect on the ultimate visual 
outcome (Margalit and Sadda, 2003). 
Unlike optic neuritis which is due to inflammation, ischemic optic neuropathy (ION) is 
due to ischemia.  ION is the most common form of optic neuropathy in older patients (review by 
Biousse and Newman, 2015).  ION can be classified as anterior- or posterior-ION based on the 
segment of the optic nerve affected, although 90% of cases present as anterior ION.  Anterior- 
and posterior-ION can be further classified as nonarteritic or arteritic (Biousse and Newman, 
2015).  Nonarteritic anterior ION results from disease of the small vessels supplying the anterior 
segment of the optic nerve, however the exact cause is unknown. Hypoperfusion of the posterior 
ciliary artery branches leads to optic nerve ischemia and compression of the axons and 
capillaries in the optic nerve head ultimately leading to axonal loss and subsequent vision loss 
(Biousse and Newman, 2015).  There are currently no established treatments for nonarteritic 
anterior ION (Biousse and Newman, 2015).  Arteritic ION is caused by inflammation of the 
arteries (arteritis), particularly the cranial branches of the aortic arch including the ophthalmic 
and ciliary arteries.  Again, the precise mechanism of the disease is unknown and may be 
determined by a wide variety of factors such as genetics, autoimmunity and environment 
(Biousse and Newman, 2015).  If the arteritis is left untreated, transient visual loss caused by 
optic nerve or choroidal ischemia precedes permanent visual loss by days to weeks (Biousse and 
Newman, 2015).  Immediate treatment is possible with the use of glucocorticosteroids to prevent 




1.2.3 Optic nerve regeneration 
Studies have focused on regenerating RGCs by targeting the same factors that prevent 
regeneration in other CNS tissues.  These factors include: preventing neuronal (RGC) cell death, 
activating the RGC growth state and counteracting inhibitory signals in the extracellular 
environment.  As in the brain and spinal cord, MAIs such as Nogo-A, MAG, and MOG suppress 
optic nerve axon growth.  Additionally, CSPGs that accumulate in the glial scar at the site of 
injury also inhibit axon growth.  Overcoming these factors can help to regenerate the optic nerve. 
 The use of trophic factors can help provide a source of neuroprotection.  The classical 
neurotrophins, namely BDNF, and neurotrophin 4/5 (NT-4/5) bind to tyrosine kinase receptors 
expressed on RGCs (Fischer and Leibinger, 2012).  Both of these molecules mediate 
proliferation, differentiation, axon growth and dendrite and synapse formation in the CNS (Ebadi 
et al., 1997).  Additionally, cytokines of the IL-6 family, namely leukemia inhibitory factor (LIF) 
and ciliary neurotrophic factor (CNTF) have also been shown to be neuroprotective (Leibinger et 
al., 2009).  Both of these cytokines involve the signal transducing receptors glycoprotein 130 
and LIF receptor, which are both expressed by RGCs (Fischer and Leibinger, 2012).  Other 
growth factors such as fibroblast growth factor (FGF), GDNF, hepatocyte growth factor (HGF) 
and granulocyte-macrophage colony stimulating factor (GM-CSF)  also increase the survival of 
RGCs after optic nerve injury (Fischer and Leibinger, 2012).  It remains unclear whether these 
growth factors have a direct effect on the RGCs or if the effects are a consequence of activating 
other retinal cells.  For example, intravitreal injection of CNTF activates retinal glia to express 
and release endogenous CNTF (Muller et al., 2009).  BDNF has been shown to be the most 
effective survival agent for axotomized RGCs, however the effects of BNDF and other factors 
are transient and only delay the progress of neuronal degeneration, as the injured axons do not 
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regrow (Di Polo et al., 1998).  Consequently, neuroprotection itself cannot be sufficient for 
complete regeneration of RGCs. 
 Benowitz’ group discovered that puncture of the ocular lens induces a robust regenerative 
response in axotomized RGCs (Leon et al., 2000).  Lens injury also enables RGCs to regenerate 
axons into the inhibitory environment of a crushed optic nerve (Leon et al., 2000; Yin et al., 
2003).  This result indicates a neuroprotective, growth promoting and disinhibitory effect on 
RGCs, because of lens injury.  The beneficial effects of the lens injury, termed inflammatory 
stimulation (IS), were attributable to the activation of retinal astrocytes/Müller cells and 
infiltrated macrophages (Muller et al., 2007; Leibinger et al., 2009).  IS induces the constant 
expression of neuroprotective CNTF and LIF in retinal astrocytes allowing for significantly 
greater neuroprotection and regeneration than compared to intravitreal administration (Muller et 
al., 2007; Leibinger et al., 2009).  Indeed, viral expression of constant CNTF allowed axons to 
reach the optic chiasm 5 weeks after an intraorbital nerve crush (Leaver et al., 2006).  Additional 
glial or macrophage-derived factors may synergistically contribute to this regeneration (Yin et 
al., 2003).  
 RGC axons are capable of growing into a peripheral nerve graft transplanted into the 
stump after transection (Aguayo et al., 1987; Vidal-Sanz et al., 1987).  These axons were able to 
grow back to and form synapses in the superior colliculi (Vidal-Sanz et al., 1987).  These studies 
indicated the inhibitory environments role in suppressing optic nerve axon growth.  Knockdown 
of Nogo receptors (NgR), the receptor family to which all three major MAIs can bind, markedly 
enhanced regeneration in the optic nerve in vivo when RGCs were also activated by lens injury, 
while knockdown of NgR alone showed almost no improvement in axonal regeneration (Fischer 
et al., 2004; Su et al., 2009).  CSPGs from the glial scar presents another source of inhibition for 
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optic nerve regeneration.  Knockout of a recently hypothesized receptor for CSPGs in mice 
demonstrated reduced sensitivity in culture and enhanced axonal regeneration beyond the scar in 
the optic nerve (Sapieha et al., 2005).  Thus, overcoming the inhibitory environment after injury 
can help to enhance axonal regeneration. 
1.3 The chick model 
1.3.1 Anatomical differences of the chick retina and optic nerve 
Development of the chick retina is like other vertebrates such as humans and rats.  Invagination 
of the optic vesicle leads to the formation of two layers.  The retina is derived from the thickened 
inner layer while the outer layer will form the sclera, choroid and retinal pigment epithelium 
(Mey and Thanos, 2000).  Retinal development is essentially completed at the time of hatching 
(Mey and Thanos, 2000).  The first cells to differentiate, in a center-to-periphery gradient are the 
RGCs, followed by the photoreceptors, amacrine cells, horizontal cells and bipolar cells (Mey 
and Thanos, 2000).  This sequence occurs in a stereotypic order but with overlap (Mey and 
Thanos, 2000).  This order differs from that of humans which occurs in two groups: retinal 
ganglion cells (RGCs), horizontal cells, and cones followed by amacrine, Müller, bipolar cells 
and rods (Oyster, 1999).  Like the fovea in human, the chick also has a region specialized for 
high visual acuity called the area centralis (Mey and Thanos, 2000).  This area extends from the 
central retina, temporal to the dorsal edge of the pectin, to the superior temporal quadrant as a 
streak (Mey and Thanos, 2000). 
Unlike humans and other vertebrates, oligodendrocyte precursors are observed in the 
inner retina around E14 (Nakazawa et al., 1993).  These cells migrate from the optic nerve into 
the retina and spread through the nerve fiber layer (Nakazawa et al., 1993).  Oligodendrocyte 
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differentiation starts during the third embryonic week and increases one week after hatching 
(Nakazawa et al., 1993).  Most of the myelination of the axons takes place during the early 
postnatal period (Mey and Thanos, 2000) 
In contrast to other vertebrates, the avian retina is devoid of blood vessels but contains 
the pectin, a vascularised organ which projects from the optic disc into the vitreous body (Mey 
and Thanos, 2000).  The vessels supplying the pectin run lateral of the optic nerve head and 
consist of several arterial and venous branches (Uehara et al., 1990).  Subsequently, 
macrophages migrate from the pectin into the periphery of the retina.  However, in humans and 
rats, these cells invade the retina from the peripheral margins via the blood vessels of the ciliary 
body and from the future central retinal artery, which passes through the optic nerve (May, 
2008). 
1.3.2 Optic nerve damage studies in chicks 
The majority of optic nerve damage studies on the chicken model have focused on regenerating 
retinal neurons.  Following excitotoxic injury to the retina, Müller glia in the retina can serve as a 
source of retinal progenitors.  However, this source is only available for the first few days post-
hatch (Fischer and Reh, 2001).  Moreover, Müller glia-derived cells in the retina either do not 
survive or fail to differentiate (Fischer and Reh, 2001).  RGC-dependent optic nerve regeneration 
is limited in the chick.  Retinae from chick embryos are able to regenerate but this ability 
declines rapidly post-hatch (Goldman and Hyde, 2014).  Fischer and colleagues (2002) induced 
damage to RGCs via kainate-induced excitotoxicity and colchicine injections, which selectively 
destroy ganglion cells.  They observed some regeneration of colchicine- and kainate-treated 
ganglion cells after intravitreal injections of growth factors insulin and FGF-2 (Fischer and Reh, 
2002).  Glucocorticoid signalling is also known to suppress inflammation and microglial and 
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macrophage reactivity (Gallina et al., 2015).  The receptors for glucocorticoid (GCR) are known 
to be localized to the nuclei of Müller glia (Gallina et al., 2015).  Fischer’s group also 
demonstrated that activation of GCRs promoted the survival of colchicine-damaged ganglion 
cells and excitotoxin-damaged amacrine and bipolar cells, and photoreceptors in detached retinas 
(Gallina et al., 2015).  The survival-promoting effects were attributable to the suppression of 
microglial activity as a result of the GCR activation in Müller glia (Gallina et al., 2015). 
1.4 Kynurenic acid 
Kynurenic acid (KYNA) is a substance that is normally found in the body in astrocytes of the 
brain (Guillemin et al., 2001).  It has activity in regulating normal physiological processes and 
has both toxic and protective effects.  However, KYNA is only one of the neuroactive 
metabolites derived from tryptophan.  Collectively, these neuroactive intermediates, termed 
“kynurenines,” have been linked to neurophysiological processes and several brain diseases.  
Illuminating the toxic or neuroprotective effects of these compounds can help to better 
understand the mechanisms responsible for CNS damage and regeneration. 
1.4.1 The kynurenine metabolic pathway 
Dietary tryptophan is metabolized via the kynurenine pathway which is initiated by the oxidative 
opening of the indole ring and eventually produces nicotinamide adenine dinucleotide (NAD+) 
(Schwarcz and Pellicciari, 2002).  L-kynurenine (L-KYN) is the major primary degradation 
product of tryptophan which subsequently leads to three neuroactive compounds.  L-KYN is 
converted to KYNA in a dead-end side-arm pathway.  L-KYN is also converted to 3-
hydroxykynurenine (3-HK) which is then converted to quinolinic acid (QUIN) eventually 
leading to NAD+ formation (Schwarcz and Pellicciari, 2002; Figure I-8). 
 
 23 
Kynurenine aminotransferases (KATs) catalyze the irreversible transamination of L-KYN 
to KYNA and metabolizes 3-HK to xanthurenic acid, an inert side product.  3-HK is also 
converted to 3-hydroxyanthranilic acid (3-HANA) by kynureninase.  3-Hydroxyanthranilic acid 
 
Figure I-8. Kynurenine metabolic pathway.  Tryptophan is metabolized to L-KYN which is 
then converted to KYNA in a dead-end side arm pathway.  L-KYN also leads to the production 
of QUIN and ultimately NAD+.  Figure reprinted from Schwarcz et al. (2002) with permission 
from the Journal of Pharmacology and Experimental Therapeutics. 
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oxygenase (3-HANAO) then converts 3-HANA to a product which rearranges non-enzymatically 
to form QUIN.  L-KYN and 3-HK can be produced by the brain but primarily enters from blood 
circulation via neutral amino acid transporters and are then taken up by astrocytes and microglial 
cells (Fukui et al., 1991).  There are two forms of KATs in the brain (KAT I and KAT II).  Both 
forms have a high affinity for L-KYN in the low millimolar range but differ in their optimum pH 
range and substrate specificity.  KAT I has a pH optimum of 9.5 to 10 with little substrate 
specificity, whereas KAT II operates best at physiological pH and preferentially recognizes L-
KYN as a substrate (Guidetti et al., 1997).  The enzymes to produce brain kynurenines are 
localized to astrocytes and microglial cells.  Astrocytes lack kynurenine 3-hydroxylase thus 
favouring KYNA production, whereas microglial cells preferentially form QUIN due to limited 
KAT activity (Guillemin et al., 2001).  The cell specific separation creates a dichotomy between 
the two metabolic arms of the pathway. 
1.4.2 Kynurenines in neurological diseases 
Huntington’s disease is an adult-onset neurodegenerative disorder caused by the expansion of a 
CAG repeat in the gene encoding huntingtin.  Huntington’s disease presents the most amount of 
evidence for a pathological role of abnormal levels of kynurenines.  QUIN was found to be 
significantly elevated to excitotoxic levels in post-mortem brains, coinciding with activation of 
microglia (Whetsell and Schwarcz, 1989).  The increase in QUIN was also associated with 
elevated levels of 3-HK (Guidetti et al., 2004).  Indeed, the elevation of both microglia-derived 
kynurenines present a synergistic neurotoxic effect (Guidetti and Schwarcz, 1999).  A reduction 




 Parkinson’s disease is a chronic neurodegenerative disorder characterized by the loss of 
dopaminergic neurons and the presence of protein aggregates (Zinger et al., 2011).  In 
Parkinson’s disease, the concentration of 3-HK is increased while kynurenine and KYNA levels 
are slightly reduced (Ogawa et al., 1992).  Moreover, QUIN levels significantly exceed KYNA 
levels, resulting in the degeneration of dopaminergic neurons in the substantia nigra of 
Parkinson’s disease patients (Tan et al., 2012).   
Alzheimer’s disease is a progressive neurological disorder characterized by impaired brain 
function due to the formation of amyloid plaques, neurofibrillary tangles, and gliosis.  In 
Alzheimer’s disease, QUIN excitotoxicity seems to be strongly associated with amyloid plaque 
formation (Guillemin et al., 2005).   
Ketamine, a drug which induces schizophrenia-like symptoms in normal individuals, and 
exacerbates psychotic features in patients with schizophrenia, functions as an NMDA receptor 
antagonist, like KYNA (Anis et al., 1983).  Indeed, KYNA levels are elevated in post-mortem 
brains of patients with schizophrenia, while 3-HK levels are unchanged (Erhardt et al., 2001; 
Schwarcz et al., 2001).  As expected, elevation of KYNA leads to a greater inhibition of 
a7nAChRs which results in an imbalance of glutamate, dopamine and acetylcholine systems in 
the brain and have all been linked to schizophrenia pathology (Erhardt and Engberg, 2002). 
Neuroinflammation plays a significant role in the pathogenesis of many neurological 
diseases.  After damage or trauma to the CNS, circulating immune cells infiltrate the brain, 
resident microglia are activated and an influx of blood derived, pro-inflammatory cytokines and 
other immune factors occurs.  These mechanisms enhance the synthesis of kynurenine from 
tryptophan within the brain (Saito et al., 1992; Saito et al., 1993).  However, the various 
cytokines have distinct roles on the activity of the enzymes involved in the production of 
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kynurenines.  After systemic lipopolysaccharide administration in rat brains, which induces 
inflammation, pro-inflammatory mediators increased the expression of kynurenine-3- 
monooxygenase leading to increased levels of 3-HK and QUIN, while KAT II expression was 
unaffected (no change in KYNA levels)(Connor et al., 2008).  MS, is a demyelinating 
autoimmune disease of the CNS characterized by the presence of peripheral immune cells within 
sites of active demyelination (Carson, 2002).  In MS patients experiencing remission, KYNA 
levels in CSF are significantly decreased.  However, in MS patients undergoing acute clinical 
exacerbation, KYNA levels are elevated in CSF and plasma (Rejdak et al., 2002; Rejdak et al., 
2007).  Thus, it’s believed that the changes in KYNA concentrations are a result of compensatory 
mechanisms to neurotoxicity.  
1.5 Drug delivery to the optic nerve 
Conventional methods of drug delivery to the eye include topical drops and intravitreal injections 
however novel drug delivery systems using nanoparticles and implants are currently being 
developed (Patel et al., 2013).  Topical eye drops are the most preferred and least invasive 
method of drug administration however the physiological and anatomical barriers of the eye 
make this a poor method of delivery to the posterior segment.  Due to rapid draining through the 
nasolacrimal ducts, low permeability of the corneal epithelium, systemic absorption and the 
blood-aqueous barrier less than 5% of a drug will reach deeper ocular tissues, making it difficult 
to achieve therapeutic drug concentrations at the posterior tissues (Patel et al., 2013).  Intravitreal 
injections are the most commonly used route of drug administration to treat posterior segment 
diseases.  However, like topical eye drops, this method does not provide a sustained delivery 
system.  The use of repeated intravitreal injections, to mimic a sustained delivery system, may 
also lead to endophthalmitis, hemorrhages and retinal detachment (Patel et al., 2013).   
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Nanoparticles are colloidal carriers that have a size range of 10 to 1000 nm (Patel et al., 
2013).  They are generally composed of lipids, proteins or natural or synthetic polymers such as 
polylactic acid (Patel et al., 2013).  Drugs can be enclosed within the polymeric shell of the 
particle and can demonstrate sustained release (Patel et al., 2013).  Following periocular 
administration in Sprague Dawley rats, 200 – 2000 nm sized particles were retained at the site of 
administration for two months (Amrite and Kompella, 2005).  More recently, trans-meningeal 
drug delivery to the optic nerve has been demonstrated using a nanoparticle delivery system with 
a controlled, sustained, release of brimonidine (Grove et al., 2014).  However, this method 
requires that the compound pass through the selectively permeable dural sheath and has only 
been demonstrated in vitro.  Nanoparticle development and testing would also be required to 
confirm delivery and flow rates of the compound.  An injection would still be required to ensure 
local delivery of the nanoparticles. 
Intraocular implants are specifically used to provide localized and sustained drug release 
over a set duration.  For posterior segment tissues, implants are typically placed intravitreally by 
making an incision at the pars plana, allowing for the delivery system to bypass the blood retinal 
barrier (Patel et al., 2013). However, this type of delivery system is still limited to delivering 
compounds from the vitreal chamber, making it difficult to ensure that an adequate dose spreads 
the full length of the optic nerve. Alzet osmotic pump implants have been used by several groups 
to deliver agents directly to the optic nerve at constant flow rates (Hodges-Savola et al., 1996; 
Rogers, 2003; Chauhan et al., 2004; Aktas et al., 2010).  However, these devices require a much 
more invasive means of targeting the tissue.  Aktas et al (2010), placed the catheters from the 
mini-pumps in the anterior portion of the optic nerve from a surgically created sub-Tenon space 
in rabbits.  In rats, Chauhan et al (2004) exposed the optic nerve by blunt dissection through an 
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incision over the orbital ridge.  A small hole in the orbital ridge was made by drilling through it.  
Then the catheter was fed through and held in place by gluing it to the ridge while leaving the 
end of the catheter just above the nerve.  Hodges-Savola (1996) and Rogers (2003) both 
dissected the superior extraocular muscles to expose the optic nerve in rabbits.  The catheter was 
then placed under the dural sheath of the nerve.  However, removal of the extraocular muscles 






The CNS, unlike the peripheral nervous system, does not readily regenerate after damage. The 
inability to successfully regenerate is thought to occur due to a non-permissive cellular 
environment following damage to the structures; inhibitory molecules, such as myelin produced 
by glial cells and inflammatory molecules, lead to the formation of a glial scar and permanent 
damage (Weibel, 1994; Hernandez, 2000).   
A study by Dabrowski and colleagues (2015) revealed that prolonged infusion of a high 
dose of kynurenic acid (KYNA) could effectively reduce the myelin content in the spinal cord 
without severe damage to the glial cells or an inflammatory cascade, illuminating a potential role 
for KYNA to act as an inhibitor of myelin production.  KYNA has also been shown to elicit 
neuroprotective effects after central nervous system (CNS) injury (Hsieh et al., 2011; Zadori et 
al., 2011; Korimova et al., 2012) indicating that changes to KYNA concentrations and prolonged 
vs single dose administration of KYNA can have markedly different effects on the 
neurophysiology of the brain and spinal cord.  Thus, it is reasonable to suspect that KYNA may 
be a useful mediator of myelin proteins during optic nerve damage, which may help to provide a 
more permissive environment for the regenerative process.  The purpose of the following study 




III: MATERIAL AND METHODS 
3.1 Animals 
All procedures in this study were conducted in accordance with the Guidelines of the Canadian 
Council on Animal Care.  All protocols were approved by the University of Waterloo Animal 
Care Committee. A total of 31 mixed, unsexed White Leghorn hatchlings (Gallus gallus 
domesticus) were obtained from Maple Leaf Poultry in New Hamburg, Ontario and were fed ad 
libitum.  Chicks were housed in stainless steel brooders with a heat source and kept on a 12 h: 12 
h light-dark cycle. The chicks were randomly assigned to one of three treatment groups. Chick 
optic nerves were unilaterally infused with either KYNA (group I), PBS (group II), or received 
no treatment (group III).  Chicks that received no treatment served as negative controls (NC). 
3.2 Implantation  
At 7 days old, chicks were induced and maintained with 2-2.5% isoflurane in oxygen.  Seven day 
old chicks were selected to provide the optimal conditions necessary for the success of the 
implantation. The skin near the left eye, head, and neck were shaved and disinfected.  An 
incision was made at the lateral canthus of the left eye (treated).  The optic nerve of the left eye 
was exposed by spreading the lateral rectus and superior rectus muscles apart.  The dura was cut 
and superficially spread apart.  A rat intrathecal catheter (0007741, Alzet, Durect Corporation, 
Cupertino, CA) was then placed between the extraocular muscles and into the nerve, under the 




A drop of Vetbond Tissue Glue (10872, CDMV, St-Hyacinthe, Quebec) was added to hold the 
catheter in place.  The catheter was also held in place with a suture to the fascia at the lateral 
canthus.  The remaining external portion of the catheter was placed under the skin toward the 
back of the head where it was connected to an osmotic pump (Model 1007D, Alzet, Durect 
Corporation, Cupertino, CA).   The pumps were pre-loaded with either KYNA (K3375, Sigma-
Aldrich, Oakville, Ontario) or PBS.  0.473 g of KYNA was diluted in 50 mL of PBS and slowly 
titrated with 1 normal NaOH to raise the pH to 7.5.  Diluted KYNA or PBS was filter-sterilized 
with a 0.2 micron syringe-top milliQ filter before being injected into the osmotic pumps.  The 
pumps were then placed subcutaneously in the lower back neck region.  The skin at the lateral 
canthus and back of the head were sutured using ophthalmic silk braided 7-0 G-6 sutures 
(104965, CDMV, St-Hyacinthe, Quebec).  After the surgery, chicks received a 0.1 mL injection 
 
Figure III-1. Illustration describing the surgical procedure with images indicating exposure 
of the optic nerve and catheter insertion.  Optic nerves were exposed by carefully spreading 
apart the extra ocular muscles.  The catheter was then inserted under the dural sheath and fixed 





of a 1:10 diluted solution of meloxicam (Metacam 0.5%, 104674, CDMV, St-Hyacinthe, 
Quebec) subcutaneously for postoperative analgesia and polysporine was generously spread over 
the incision and implantation sites.  The right eye (control) of the birds that underwent surgery 
was left untouched.  Chicks received subdural infusion of either KYNA or PBS, at a flow rate of 
0.5 µl/hr, for seven days into the left optic nerve.  All chicks were monitored daily for signs of 
complications and general health. 
KYNA-infused, PBS-infused, and birds that received no treatment were euthanized with 
an intraperitoneal injection of 75 mg/kg body weight sodium pentobarbital (McGill University, 
Quebec) and the chest was opened.  A dose of 100 IU heparin (105763, CDMV, St-Hyacinthe, 
Quebec) was injected into the left ventricle prior to cardiac perfusion with lactated Ringer’s 
solution (4395, CDMV, St-Hyacinthe, Quebec).  For histology and electron microscopy birds 
were perfused with Karnowski’s fixative following the lactated Ringer’s solution. 
3.2.1 Validation of the implantation technique 
A subset of chicks was used to validate the surgical procedure by infusing the nerves with India 
ink.  Chicks that were infused with India ink into the left nerve show a clear color change due to 
the infiltration of the black dye (Figure III-2).   The dye was present throughout the optic chiasm 
and the contralateral nerve.  In contrast, the negative control and PBS-infused birds did not show 
any colour change (Figure III-2). 
3.3 Histology and electron microscopy 
The tissues of the brain and optic nerve of KYNA-infused (n = 7), PBS-infused (n = 3) and 
negative controls (n = 4) chicks were removed carefully and post fixed in Karnowski’s.  During 
the dissection, nerves were inspected to confirm the location of the catheter within the nerve.  
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Optic nerves were cut and submitted to the HSC Electron Microscopy Facility at McMaster 
University for embedding in epon/aradite resin.  For histology, 1 µm thick sections, from the 
optic nerve head, were cut with a glass knife, mounted on a glass slide and stained with toluidine 
blue.  These sections were analyzed under a Nikon Eclipse 50i microscope.  Silver gray ultrathin 
sections from epon-embedded portions of the nerve were mounted on Formvar coated copper 
grids, stained with uranyl acetate and lead citrate and examined under a Jeol 1200EX Biosystem 
transmission electron microscope.  Histology was assessed qualitatively and quantitatively. 
3.3.1 Axon counts and g-ratios 
Electron microscope (EM) images, of 0.01 mm² areas, were sampled from four equidistant 
quadrants of the optic nerve (Figure III-3A).  The number of myelinated and unmyelinated axons 
were counted from each of the four quadrants using ImageJ (http://imagej.nih.gov/ij/; provided 
in the public domain by the National Institutes of Health, Bethesda, MD, USA).  Degenerating 
axons, and axons not completely within the image area were also not counted.  The mean 
 
Figure III-2.  Validation of the implant procedure.  Dissected Negative control (A), PBS-
infused (B), and India Ink-infused (C) optic pathways and brain matter.  India Ink-infused birds 




percentage of myelinated:unmyelinated axons were calculated for each quadrant and averaged.  
The mean g-ratio, which consists of the axon diameter/myelin diameter, of 25 randomly selected 
axons from each of the four quadrants (total axons measured = 100) were also averaged and 
calculated using a modified version of an ImageJ plugin (Goebbels et al., 2010).  Axons were 
randomly selected by the plugin, by randomly placing a cross on the image.  If the cross fell 
within an axon, its g-ratio was determined.  This version of the ImageJ plugin allows the user to 
trace the area of the oligodendrocyte inner tongue if present, thus allowing for a more accurate 
calculation of the axon and myelin diameter (Figure III-3).  The axon diameters were compared 
across the three groups.  Lastly, the number of astrocytes within each of the four quadrants were 
also counted and compared across the three treatment groups. 
3.4 Western blots and ELISAs 
Blood from the left cardiac ventricles of KYNA-infused (n = 6), PBS-infused (n = 5) and 
negative control (n = 6) chicks were collected into 5 ml syringes using a 23G needle, and 
aliquoted into 1.5 mL Eppendorf tubes prior to injecting the 100 IU of heparin.  The tubes were 
 
Figure III-3.  EM image analysis method.  A) Four equidistant quadrants were sampled from 
both optic nerves.  Total myelinated and unmyelinated axons were counted within the sampled 
area.  B-C) For each of the four sampled quadrants, g-ratios were calculated for 25 randomly 
selected axons using ImageJ. 








left undisturbed for 30 minutes before centrifuging at 2000xg for 10 minutes to separate the 
serum.  Serum was then collected and stored at -80°C until assayed. The tissues of the brain and 
optic nerve were removed carefully and stored at -80°C until assayed.  During the dissection, 
nerves were inspected to confirm the location of the catheter within the nerve. 
Enzyme-linked immunosorbent assay (ELISA) kits for anti-chicken proteolipid protein-1 
(PLP1; LS-F14513, Cedarlane, Burlington, Ontario) and anti-chicken myelin basic protein 
(MBP; LS-F14742, Cedarlane, Burlington, Ontario) were used to determine the concentration of 
these respective proteins in the animal serum.  Serum samples were not diluted and were tested 
in quadruplicate for both ELISAs.  Plates were read on a SpectraMax M5 (Molecular Devices, 
Sunnyvale, CA, USA) using SoftMax® Pro 5 (Molecular Devices, Sunnyvale, CA, USA) 
software.  The SoftMax® Pro 5 software was also used to determine the best-fit equation for the 
standard curve based on the ELISA kits recommended fit.  For the PLP1 ELISA assay a four-
parameter logistic curve was determined, 𝑦 = ($%&)
() *+
, + 𝐷, while a linear equation was used for 
the MBP ELISA assay, log 𝑦 = 	𝐴 + 𝐵 ∗ 𝑙𝑜𝑔(𝑥), with R2 values of 0.99 for both equations. 
Optic nerves of KYNA-infused (n = 4), PBS-infused (n = 4) and negative control (n = 4) 
chicks were washed with ice-cold PBS and sonicated on ice using a Branson Sonifier 450 
(VWR, Mississauga, Ontario, Canada) in an ice-cold sample buffer cocktail containing 50 mM 
Tris, pH 6.8, 2.5% glycerol, 5% SDS (71736, Sigma-Aldrich, Oakville, Ontario), 4M urea with 
Protease Inhibitor Cocktail (P8340, Sigma-Aldrich, Oakville, Ontario) and Phosphatase Inhibitor 
Cocktails (P2850 and P5726, Sigma-Aldrich, Oakville, Ontario).  The homogenate was then 
centrifuged at 10000xg for 15 min at 4ºC.  The supernatant was transferred and the protein 
concentration was measured using a DC Protein Assay Kit II (5000122, Bio-Rad Laboratories, 
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Mississauga, Ontario) with a SpectraMax M5 (Molecular Devices, Sunnyvale, CA, USA) 
spectrophotometer.  The protein concentrations were equalized by adding additional sample 
buffer cocktail.  15 µg of protein from each sample was aliquoted into separate tubes with an 
equal volume of sample buffer cocktail with 0.01% bromophenol blue and 10mM Dithiothreitol 
(DTT; 1610610, Bio-Rad Laboratories, Mississauga, Ontario).  Samples were boiled for 5 
minutes at 95 ºC prior to loading the gel wells.  A dual colour standard (1610374, Bio-Rad 
Laboratories, Mississauga, Ontario) was used as a ladder.   
Protein samples were separated by SDS-PAGE using 12% Mini-Protein TGX Precast 
Protein Gels (4561046DC, Bio-Rad Laboratories, Mississauga, Ontario) at 200 V for 45 minutes 
in the Bio-Rad Mini-Protean System (165-8000, Bio-Rad Laboratories, Mississauga, Ontario).  
Each gel was transferred to a 0.2 µm Immun-Blot PVDF membranes (1620174, Bio-Rad 
Laboratories, Mississauga, Ontario) for 45 mins at 100 V.  Transfer of the proteins was 
confirmed by flooding the PVDF membrane with a Ponceau S staining solution for 1 hour at 
room temperature.  The Ponceau S stain was then washed out completely with distilled deionized 
water. 
Blocking for nonspecific binding was performed with 5% skim milk in Tris-Buffered 
Saline (1706435, Bio-Rad Laboratories, Mississauga, Ontario) containing 0.01% Tween 20 
(TTBS) for 1 hour at room temperature.  Membranes were incubated overnight at 4ºC with 
primary antibodies for MBP, PLP, MAG and GFAP (Table III-1) diluted in blocking solution.  
MAG primary antibodies were used to probe against membranes obtained from non-reducing 
gels.  Blots were then washed with TTBS three times for 10 minutes each at room temperature 
with gentle agitation.  Membranes were then incubated with the appropriate secondary horse 
radish peroxidase (HRP) conjugated antibody (Table III-1), diluted in the same blocking 
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solution, for 1.5 hours at room temperature, followed by washing in TTBS three times for 10 
minutes each at room temperature.  Membranes were then treated with Amersham ECL Western 
Blotting Chemiluminescence Detection Reagent (GERPN223, Sigma-Aldrich, Oakville, Ontario) 
for 5 minutes and photographed using a Nikon T2i SLR camera (courtesy of Varadhu 
Jayakumar) with a 60 second exposure time. 
The above membranes were then stripped with Restore Western Blot Stripping Buffer 
(21059, ThermoFisher Scientific, Burlington, Ontario) and washed with TTBS three times for 10 
minutes each.  Membranes were blocked as above and incubated overnight at 4ºC with primary 
anti-β-actin (Table III-1) as a loading control.  Membranes were washed again as above and 
incubated with the appropriate secondary HRP antibody (Table III-1) for 1.5 hour at room 
temperature.  The membranes were washed in TTBS and treated with Amersham ECL Western 
Blotting Chemiluminescence Detection Reagent for 5 minutes and photographed as above. 
 
The specific bands were compared by densitometry analysis using ImageStudioLite 
software (LI-COR Biosciences, Lincoln, NE, USA).  Protein levels for the markers of interest 
were normalized against β-actin levels. 
Table III-1.  Primary and secondary antibodies used for western blot analysis. 
Type Antigen Host Dilution Source 
Primary MBP Rat 1:2000 MAB386, EMD Millipore 
PLP Rabbit 1:1000 ab105784, abcam 
MAG Mouse 1:500 MAB1567, EMD Millipore 
GFAP Mouse 1:500 G3893, Sigma-Aldrich 
b-actin Mouse 1:1000 ab8224, abcam 
Secondary Rat IgG HRP Goat 1:30000 (MBP) ab97057, abcam 
Rabbit IgG HRP Goat 1:30000 (PLP) ab6721, abcam 





3.5 Statistical analysis 
For the percent of myelinated axons, g-ratios, axon diameters and western blot data, a 2x3 mixed 
model ANOVA (Statistica 8.0, Statsoft, Boston, MA, USA) was used to determine differences 
between eyes (treated vs control) and treatment groups (KYNA-infused, PBS-infused, and no 
treatment).  Tukey-HSD post hoc tests were used to determine any differences between treatment 
groups.  Bonferroni post hoc tests were used to determine any differences between eyes.  ELISA 
data were analysed using a one-way ANOVA to determine differences between treatment groups.  
Kruskal-Wallis ANOVAs were used to compare astrocyte cell counts across treatment groups for 
each eye.  For all tests, differences were considered significant if P < 0.05.  All means are 





4.1 Histology and electron microscopy 
The chick optic nerve is an ovoid structure that contains prominent pial vasculature with thick 
walls, oligodendrocytes, astrocytes and a mixture of large myelinated axons and numerous 
clusters of small diameter unmyelinated axons ( Figure III-3)  Although the infusion of PBS had 
no effect on the histological appearance of the optic nerve (Figure IV-2), the infusion of KYNA 
resulted in a remarkable loss of myelin sheaths and an increase in the number of glial cells 
(Figure IV-3).  Infusion of 50 mM of KYNA for 1 week resulted in large areas of myelin loss 
with no inflammatory response, preservation of normal morphology of most axons, astrogliosis 
and evidence of axonal degeneration in a small number of axons.  The contralateral optic nerve 
of KYNA-infused chicks had some myelin loss, but not to the extent of the implanted nerve 
(Figure IV-3). 
The mean percent of myelinated axons was not statistically different between the treatment 
groups (p = 0.0936) or between the eye (p = 0.0537).  No interaction between the eyes and 
treatment group was observed (p = 0.1852).  However, the data for the percent of myelinated 
axons from the treated eye (left eye) violates the assumption of homogeneity of variances 
(Levene’s test, p = 0.0012) and likely affects the results of the statistical test.  Also, a lack of 
power for the treatment (p = 0.4599), eye (p = 0.5042) and interaction (p = 0.3222) effects likely 
compromise the results of this ANOVA.  It appears 3 out of the 7 treated optic nerves from 
KYNA-infused birds were seemingly unaffected by the treatment resulting in a bimodal 
distribution within this subset of the data ( Figure IV-4A).  A greater sample size may be 
required to demonstrate a significant statistical effect.  However, mean g-ratios were statistically 
different across treatment groups (p = 0.0037) and between eyes (p = 0.0005;  Figure IV-4B).  
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Irrespective of the eye, mean g-ratios for KYNA-infused chicks were greater than those for 
negative control birds (0.86 ± 0.04 for KYNA vs 0.78 ± 0.02 for NC; p = 0.0029) but were not 
significantly greater than compared to PBS-infused chicks (0.83 ± 0.06; p = 0.2605).  Mean g-
ratios for PBS-infused birds were also not significantly different than those for negative control 
birds (0.83 ± 0.06 for PBS vs 0.78 ± 0.02 for NC; p = 0.1333).  Axon diameters were not 
statistically different across treatment groups (p = 0.7500) nor between eyes (p = 0.9204) nor as 
an interaction between treatment groups and eyes (p = 0.8500; Figure IV-5A).  A main effect in 
the left eye, across treatment groups, was found for the mean number of astrocytes (p = 0.0329), 
however no post-hoc differences were found within the left eye (p > 0.1449).  Meanwhile, the 
right eye was not statistically different across treatment groups (p = 0.5533).  
4.2 ELISA and western blots 
The concentrations of both PLP1 and MBP, in the chick serum, were not dependent on the 
treatment group (p = 0.8759 and p = 0.8330, respectively; Table IV-1).  On the other hand, 
qualitative differences were observed in the western blots for the various proteins of interest 
(Figure IV-6A).  Bands for both isoforms of MBP, and PLP showed qualitatively reduced levels 
in KYNA-infused birds compared to PBS-infused and negative control birds.  Moreover, the 
implanted eye qualitatively appeared to have a further reduction of these myelin proteins 
compared to the contralateral optic nerve.  A statistically significant interaction effect was 
detected for MBP 1 (20 kDa isoform), MBP 2 (12 kDa isoform) and PLP (p = 0.0113, p = 
0.0063, p = 0.0461, respectively), however, no post-hoc significant effects were detected, nor 
were there any main effects across treatment groups (p = 0.0914, p = 0.5749, p = 03592, 
respectively), nor a main effect between eyes (p = 0.0563, p = 0.9431, p = 0.5351, respectively). 





Figure IV-1.  Morphology and features of the normal chicken optic nerve.  A-B) Toluidine 
blue stained cross-section of a 14-day old normal chick optic nerve.  Arrows indicate the thick 
pial vasculature visualized by dark staining regions on the chick optic nerve.  C-D) EM cross-
section of a 14-day old normal chick optic nerve blood vessel (bv), oligodendrocyte (OL), axon 
(Ax) and population of unmyelinated axons (dashed circle). 

















Figure IV-2.  Effect of subdural infusion on the implanted and contralateral optic nerves 
for PBS-infused chicks.  A-B) Toluidine blue and EM (C-D) images for PBS infused nerves.  
Both the implanted nerve (C) and contralateral nerve (D) showed little to no myelin loss. 













Figure IV-3.  Effect of subdural infusion on the implanted and contralateral optic nerves 
for KYNA-infused chicks.  A-B) Toluidine blue and EM (C-F) images for KYNA-infused 
nerves.  The implanted nerve (A-D) showed severe myelin loss.  The contralateral nerve (E-F) 
exhibited some localized regions of myelin loss (F). 
500 µm 50 µm
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 Figure IV-4.  Mean percent of myelinated axons (A,) and mean g-ratios (B) for negative 
control (NC), PBS-infused and KYNA-infused birds.  Groups denoted by the same letter(s) 
are not significantly different.  Middle bar represents the mean.  Box value represents 1 standard 


















































Figure IV-5.  Mean axon diameter (A) and mean number of astrocytes (B) for both eyes 
across negative control (NC), PBS-infused, and KYNA-infused birds.  Mean axon diameters 
were not different across treatment groups (p = 0.7500).  A main effect in the left eye was 




















































compared to either the PBS-infused and negative control birds.  The relative intensities for MAG 
were also not dependent on the treatment group (p = 0.4610) nor which eye (p = 0.6190) nor was 
an interaction effect detected (p = 0.2630).  Interestingly, qualitatively, GFAP appeared to be 
elevated in the PBS-infused nerves compared to either the KYNA-infused or negative control 
birds, however, these differences were not statistically significant.  Relative GFAP intensities 
were not dependent on the treatment group (p = 0.3942) nor which eye (p = 0.3999) nor was an 
interaction effect detected (p = 0.1079). 
 
Table IV-1. Mean serum concentrations of PLP1 and MBP for KYNA-treated, PBS-treated 
and negative control birds. 
Treatment Group PLP1 (ng/ml) MBP (ng/ml) 
KYNA (n=6) 0.75 ± 0.23 1.26 ± 0.11 
PBS (n=5) 0.76 ± 0.19 1.28 ± 0.07 
negative controls (n=6) 0.81 ± 0.21 1.30 ± 0.11 
The concentrations of PLP1 and MBP, in the chick serum, were not dependent on the 




Figure IV-6. Semi-quantitative analysis of western blots data.  A) Representative western 
blots of the left (L) and right (R) eyes for KYNA-infused, PBS-infused and negative control 
(NC) birds.  B-F) Band intensities as a percent relative to β-actin levels, for each of the treatment 
groups.  Bars represent mean ± SE. 
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The method used in the following experiments, to deliver KYNA to the optic nerve in vivo, has 
not been previously reported in a chicken model.  A similar method, using implanted ALZET 
osmotic pumps in New Zealand White rabbit optic nerves, has been used to deliver isoproterenol 
(Hodges-Savola et al., 1996) and kainate (Matute et al., 1997; Soto et al., 2004) through 
continuous infusion.  However, the implantation procedure performed by these groups involve 
dissection of the superior extraocular muscles.  Unlike the chicken, the rabbit optic nerve, like 
that of other mammals, has a central retinal artery (May, 2008).  Both dissection of the muscles 
and the presence of the central retinal artery provide reasons to opt for the chicken model.   The 
Dissection of the muscles may have an effect on the development and growth of the eye by 
deregulating binocular vision and altering the biomechanical properties of the eyeball (Greene, 
1981; Zhou et al., 2011).  Moreover, inserting a catheter for infusion of the compound of interest 
may affect blood flow in the optic nerve, introducing the possible ischaemic effects.  Our 
surgical procedure indicates successful delivery of an agent, over 7 days.  The presence of India 
ink in the surgically treated nerve, the contralateral nerve, and the optic chiasm indicates a wide 
distribution of the delivered agent (Figure III-2).  However, it is unclear if the distribution of the 
agent is equal across the entire visual pathway.  Given the that catheter is placed in the left nerve, 
it’s likely the left nerve receives a greater amount of the delivered agent than the other structures.  
It is also unclear to what extent the compound spreads through the visual pathway and the rest of 
the brain.  Given that no obvious dark staining was observed beyond the chiasm it is likely that 
any agents that reach these areas are negligible in dose and consequently its effect.  It’s also 
possible that some of the agent flows into the eye, possibly affecting the retina.  Unlike other 
animals, chicken retinas contain oligodendrocytes and are consequently myelinated during 
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embryonic development (Nakazawa et al., 1993).  Subsequently, administration of KYNA could 
have had an effect on the degree of myelination within the retina and subsequently effect the 
downstream pathway.  Confirmation of any effect of KYNA on the retina, through administration 
via the optic nerve, would need further study.  That the negative control and PBS-infused visual 
pathways have a similar appearance suggests that the surgical procedure does not result in severe 
or permanent damage to these tissues.  The lack of major superficial damage provides further 
reason to use this surgical method to deliver agents to the optic nerve, without the need for 
dissecting extraocular muscles. 
 Histological images obtained from negative control, PBS-infused, and KYNA-infused 
birds revealed remarkable differences.  As expected, KYNA-infused birds demonstrated a 
remarkable loss of myelin while preserving normal axonal morphology (Figure IV-3).  
Additionally, a surprising number of reactive astrocytes were present in KYNA-infused electron 
micrographs.  In contrast, both the PBS-infused and negative control bird’s electron micrographs 
appeared similar with no remarkable changes in the level or appearance of myelinated axons, or 
the number of astrocytes (Figure IV-2).  None of the toluidine blue stained images or electron 
micrographs for any of the treatment groups showed signs of inflammatory infiltration.  These 
data correspond well to a previous study by Dabrowski and colleagues (2015) in which KYNA-
infused rat spinal cords demonstrated similar effects and did not lead to inflammation.  A recent 
study by Langner and colleagues (2017) has also revealed that high concentrations of KYNA 
affect the viability and metabolic activity of oligodendroglial cells in vitro but did not have an 
effect on the oligodendroglial cell proliferation and morphology.  Langner and colleagues (2017) 
also demonstrated the effect of KYNA to be independent of its role as a glutamate receptor 
antagonist.  Consequently, the mechanism by which KYNA affects oligodendrocytes and their 
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ability to wrap axons with myelin may be related to its role as an α7 nicotinic acetylcholine 
(α7nACh) receptor antagonist or G-protein-coupled receptor 35 (GPR35) agonist.  Expression of 
GPR35 mRNA has been observed in rat spinal cords and dorsal root ganglion (Ohshiro et al., 
2008) as well as in mouse astrocytes (Berlinguer-Palmini et al., 2013).  Furthermore, KYNA 
may induce the production of inositol phosphate and elicit Ca2+ mobilization (Divorty et al., 
2015).  Studies have suggested that GPR35 can modulate inflammatory conditions.  Through the 
GPR35 receptor, agonists like kynurenic acid have been demonstrated to attenuate inflammatory 
processes and inhibit the release of tumor necrosis factor α (Wang et al., 2006; Kuc et al., 2008; 
Barth et al., 2009; Thorburn et al., 2014).  These additional attributes in conjunction or 
separately may be involved in the mechanism by which myelin loss is occurring. 
The non-significant differences between the percent of myelinated nerve fibers across 
treatment groups was unexpected.  However, it is likely that the lack of significance was due to 
the binomial distribution of data within the left eye of the KYNA-treated nerves ( Figure IV-4A).  
Three out of the seven KYNA-infused birds did not demonstrate the same proportion of axons 
with total myelin loss as the other birds ( Figure IV-4A).  It is unclear why these three birds were 
less affected by administration of KYNA.  It is possible that the surgery was not successful in 
these three birds, although, during dissection of the nerves, the location and presence of the 
catheter is confirmed.  Moreover, the pumps were inspected to ensure there was no residual 
volume left over.  Nonetheless, it’s conceivable that the variations in the location or perfusion 
characteristics produced lower delivery to the target organ.  Also, it’s possible that damage to the 
sheath on the opposite side of the nerve led to another point of drainage, also leading to 
inadequate delivery of the agent to the nerve.  Although the percent of myelinated axons varied 
for KYNA-infused birds, a more consistent effect on axon g-ratios indicates an overall change in 
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the degree of myelination.  The g-ratios provide a more robust means of analyzing the effect of 
PBS or KYNA on the optic nerves compared to negative controls.  An inability to determine 
statistical differences in g-ratios between eyes of the three treatment groups suggests that agent 
delivery occurs in substantial amounts across the nerves and chiasm resulting in proportional 
effect on both nerves.  The slightly larger g-ratios in the left eyes, for both PBS- and KYNA-
infused birds, may also be associated with damage inflicted by the surgical procedure ( Figure 
IV-4).  Given that a foreign object is being implanted in the nerve for 7 days, and CSF is being 
displaced by PBS or KYNA diluted in PBS, it is likely that this damaging effect is responsible 
for the larger g-ratios.  That axon diameters revealed no significant differences indicates a direct 
change in the degree of myelination, while axonal morphology was unaffected (Figure IV-5A).  
As noted in electron micrographs, KYNA-infused birds displayed astrogliosis as characterized 
by a difference in the mean number of astrocytes in the implanted nerves (Figure IV-5B). 
 That no significant difference was found, between the concentration of serum MBP and 
PLP-1 for the three treatment groups, suggests that the mechanism of myelin loss is non-
destructive in nature (Table IV-1).  Other studies have demonstrated that in patients suffering 
from traumatic brain injury (TBI), MBP concentrations in serum were elevated and strongly 
correlated with the severity of the injury (Thomas et al., 1978; Berger et al., 2007).  Moreover, 
neurologically impaired patients, such as those with demyelinating and encephalitic diseases 
have also demonstrated elevated serum concentrations of PLP (Trotter et al., 1983) and MBP 
(Ohta et al., 2002).  Antibodies against myelin proteins are also elevated in the serum of 
relapsing-remitting MS patients (Angelucci et al., 2005).  These neurological injuries involve a 
destructive and damaging mechanism leading to elevated concentrations of myelin proteins in 
the patient serum.  In contrast, due to the non-inflammatory nature of the KYNA-associated 
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myelin loss, myelin from the optic nerve is likely not being damaged or destroyed but retracted 
through its effects on oligodendrocytes. 
 A qualitative decrease in the MBP isoforms and PLP in KYNA-infused birds correlates 
well with the elevated g-ratios in the electron microscopy images.  Moreover, given that there is 
a qualitative reduction in these proteins in the optic nerve, without an elevation of these proteins 
in serum, further suggests a non-destructive, non-inflammatory nature of myelin loss.  The lack 
of a qualitative decrease of MAG in the KYNA-infused birds was surprising given that the other 
myelin proteins showed slight decreases.  However, unlike MBP or PLP, MAG has key functions 
in myelin maintenance.  MAG acts as both a ligand for the axonal NgR receptor and as a 
receptor for axonal signalling that promotes differentiation, maintenance and the survival of 
oligodendrocytes (Quarles, 2007).  In CNS MAG-deficient mice, the initiation of myelination, 
formation of intact myelin sheaths and the integrity is affected.  Thus, it is possible that MAG 
expression is modulated in response to the KYNA-associated myelin loss, as a means of 
counteracting KYNAs’ effects on the viability of oligodendrocytes within the nerve.  Injury to 
the brain and CNS tissue triggers astrocytes to become reactive, which involves the upregulation 
of GFAP and changes in astrocyte morphology (Vanezis et al., 1987; Hatten et al., 188).  Indeed, 
glaucoma models in mice have also demonstrated an elevated expression of GFAP in western 
blots of optic nerves (Joos et al., 2010; Sun et al., 2013).  The elevation of GFAP was a 
consequence of the injury to the retinal ganglion cells via intraocular pressure elevation.  
Subsequently, the observation that GFAP was elevated in PBS-infused nerves was expected 
given the traumatic and injury-inducing nature of the surgical implant.  However, given that 
KYNA-infused birds underwent the same surgical procedure and appeared to have a greater 
amount of astrogliosis, the lack of elevated GFAP in these birds seems contradictory.  Through 
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KYNA’s agonistic interaction with the GPR35 receptor located on astrocytes of the CNS, a 
reduction of intracellular cyclic adenine monophosphate (cAMP) has been demonstrated 
(Berlinguer-Palmini et al., 2013).  Elevated intracellular cAMP is required for the induction of 
GFAP expression in astrocytes (Roymans et al., 2001).  Therefore, its plausible that KYNAs 
inhibition of intracellular cAMP may be subsequently modulating the expected increase in GFAP 
expression.  Furthermore, the anti-inflammatory properties of KYNA may also further diminish 
the activation of GFAP in astrocytes.  That a statistical difference was not detected, between the 
treatment groups for western blot proteins, is likely due to the low sample size and consequently 
low power of the statistical tests.  Moreover, the effects of infusion on these birds seemed to have 
more robust effects in localized regions of the nerve.  Hence, a semi-quantitative western blot 
analysis of the entire optic nerve may not be sensitive enough to detect overall changes in the 
nerve. 
 In summary, infusion of KYNA into the implanted optic nerves of chickens was 
associated with myelin loss.  The myelin loss, characterized by changes in axon g-ratios and 
western blots of the optic nerve indicate an overall reduction in the level of major myelin 
components, MBP and PLP.  A lack of: a histological inflammatory response, a change in serum 
myelin concentration, and an elevation of GFAP indicates an inflammation suppressing effect of 
KYNA that could be useful as a tool for regeneration.  However, further studies are required to 
elucidate the long-term effects of administration of KYNA.  Oligodendrocyte and myelin revival 
are essential for complete recovery after injury to CNS tissue.  Thus, determining the optimal 
concentration of KYNA to induce myelin loss and suppress inflammation after injury, is required 
to ensure an appropriate recovery time for the tissue and oligodendrocytes.  The functional 
effects of administration of KYNA have yet to be determined.  Administration of KYNA into the 
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retina and optic nerves of chickens may be a useful method to study the functional deficits that 
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